The rationale for aerosolized antibiotics

Pharmacotherapy

Volumn 22, Issue 3 I, 2002, Pages

  Flume, Patrick ^a   Klepser, Michael E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TOBRAMYCIN;

AEROSOL; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; CONCENTRATION RESPONSE; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; FORCED EXPIRATORY VOLUME; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PSEUDOMONAS;

EID: 0036198938     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.6.71s.33909     Document Type: Conference Paper

References (22)

1. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
2. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
3. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems
4. Safety and efficacy of tobramycin solution for inhalation in patients with cystic fibrosis: The results of two phase III placebo controlled clinical trials
5. Survival of patients with cystic fibrosis
6. The changing epidemiology of cystic fibrosis
7. Epidemiologic study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada
8. Clinical outcome after early Pseudomonas aeruguiosa infection in cystic fibrosis
9. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis
10. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
11. New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis
12. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
13. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
14. Administration of aerosolized antibiotics in cystic fibrosis patients
15. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
16. Microbiological and immunologic considerations with aerosolized drug delivery
17. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
18. Microbiology effect of 18 months of intermittent inhaled tobramycin in patients with CF
19. Bronchiectasis: Update of an orphan disease
20. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis
21. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies